Stock Analysts’ updated eps estimates for Thursday, January 20th: Hoth Therapeutics (NASDAQ:HOTH) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Hoth Therapeutics Inc. is a development stage biopharmaceutical company. It focused on therapeutics for patients suffering from indications such as atopic dermatitis, also known […]